{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457633911
| IUPAC_name = 2-''sec''-Butyl-2-methylpropane-1,3-diyl dicarbamate
| image =  Mebutamate.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Schedule IV
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 64-55-1
| ATC_prefix = N05
| ATC_suffix = BC04
| PubChem = 6151
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5H8F175RER
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01807
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200922
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 5919

<!--Chemical data-->
| C=10 | H=20 | N=2 | O=4 
| molecular_weight = 232.277 g/mol
| smiles            = CCC(C)C(C)(COC(=O)N)COC(=O)N
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = LEROTMJVBFSIMP-UHFFFAOYSA-N
}}

'''Mebutamate''' ('''Capla''', '''Dormate''') is an [[anxiolytic]] and [[sedative]] [[drug]] with [[antihypertensive]] effects of the carbamate class.<ref name="TaylorFrancis2000">{{cite book | title = Index Nominum 2000: International Drug Directory | url = https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA634 | date = January 2000 | publisher = Taylor & Francis | isbn = 978-3-88763-075-1 | page = 634}}</ref><ref>{{ cite book | title = The Merck Index | edition = 14 | publisher = Merck Publishers | isbn = 978-0-911910-00-1 | at = 5813 }}</ref> It has effects comparable to those of [[barbiturate]]s such as [[secobarbital]], but is only around 1/3 the potency of secobarbital as a sedative. Side effects include [[dizziness]] and [[headaches]].<ref>{{Cite journal 
| last1 = Tetreault | first1 = L. 
| last2 = Richer | first2 = P. 
| last3 = Bordeleau | first3 = J. M. 
| title = Hypnotic properties of mebutamate: A comparative study of mebutamate, secobarbital and placebo in psychiatric patients 
| journal = Canadian Medical Association journal 
| volume = 97 
| issue = 8 
| pages = 395–398 
| year = 1967 
| pmid = 6037393 
| pmc = 1923261
}}</ref>

Mebutamate is one of many [[Gabaergic|GABAergic]] drugs which act via [[allosteric]] agonism of the [[GABAA receptor|GABA<sub>A</sub> receptor]] at the β-subreceptor similar to barbiturates. In contrast, [[benzodiazepines]] act at the α-subreceptor. As such, carbamates and barbiturates, possess analgesic properties which the benzodiazepine class of drugs do not.

Other carbamates with the same mechanism of action and pharmacological properties include [[meprobamate]], [[carisoprodol]], [[felbamate]], and [[tybamate]]).

==Synthesis==
[[File:Mebutamate synthesis.svg|thumb|center|700px|Mebutamate synthesis: Berger, Ludwig, {{US patent|2878280}} (1959 to [[Carter-Wallace|Carter Prod]].).]]

==[[Structural analog]]s==
*[[Lorbamate]]
*[[Carisoprodol]]
*[[Pentabamate]]
*Mebutamate
*[[Meprobamate]]
*[[Felbamate]]
*[[Tybamate]]

== References ==
{{Reflist}}

{{Anxiolytics}}
{{GABAAR PAMs}}

[[Category:Anxiolytics]]
[[Category:Carbamates]]
[[Category:GABAA receptor positive allosteric modulators]]


{{nervous-system-drug-stub}}